schizophrenia - Articles and news items

Braeburn achieves endpoints in implant study to treat Schizophrenia

Industry news / 8 May 2017 / Niamh Marriott, Junior Editor

Braeburn Pharmaceuticals’ 6-month study of the safety, tolerability and pharmacokinetics of transferring patients diagnosed with schizophrenia…

Alexza granted FDA approval of Adasuve sNDA to treat schizophrenia

Industry news / 11 October 2016 / Niamh Louise Marriott, Digital Content Producer

Administration of Adasuve results in rapid absorption of loxapine, with a maximum plasma concentration achieved in approximately 2 minutes…

EC approves Trevicta for the treatment of schizophrenia

Industry news / 1 June 2016 / Victoria White, Digital Content Producer

The EC has approved the use of Trevicta (paliperidone palmitate a 3-monthly injection) for the maintenance treatment of schizophrenia in adult patients…

CHMP adopts positive opinion of Trevicta for maintenance treatment of schizophrenia

Industry news / 5 April 2016 / Victoria White

If approved, this 3‑monthly injection will allow patients to maintain an optimal level of treatment in their blood with fewer administrations…

Lundbeck starts Lu AF35700 Phase III programme in treatment-resistant schizophrenia

Industry news / 14 March 2016 / Victoria White

The Phase III programme will consist of two pivotal trials. Two doses of Lu AF35700 will be tested in patients with treatment resistant schizophrenia…

Positive Phase 1b results for Heptares’ HTL9936

Industry news / 10 February 2016 / Victoria White

HTL9936 is the first selective muscarinic M1 receptor agonist which has entered clinical development as a new treatment for cognitive impairment in patients with dementia and schizophrenia…

FDA approves schizophrenia treatment Aristada

Industry news / 7 October 2015 / Victoria White

Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection…

New data released from QUALIFY study of aripiprazole once-monthly

Industry news / 24 June 2015 / Victoria White

Otsuka and Lundbeck have announced newly released subgroup analysis of data from the QUALIFY study of Abilify Maintena (aripiprazole once-monthly)…

Johnson & Johnson and collaborators launch the Open Translational Science Project in Schizophrenia

Industry news / 9 June 2015 / Victoria White

Johnson & Johnson and a group of leading research organisations are launching the OPTICS Project – Open Translational Science in Schizophrenia…

Positive top-line results from Phase 3 trial of RBP-7000 in schizophrenia announced

Industry news / 6 May 2015 / Victoria White

Indivior has announced top-line results from its Phase 3 clinical trial of RBP-7000, an investigational drug for the treatment of schizophrenia…

Pierre Fabre Pharmaceuticals starts Phase IIa trial for F17464

Pierre Fabre Pharmaceuticals announce initiation of Phase IIa clinical trial program for F17464 in schizophrenia

Industry news / 3 February 2015 / Pierre Fabre Pharmaceuticals

Pierre Fabre Pharmaceuticals has announced the initiation of a Phase IIa clinical trial program for F17464, a new selective dopamine D3 receptor antagonist, in schizophrenia. The trial is designed to assess the efficacy and safety of F17464 compared to placebo in patients with acute schizophrenia. The six-week multinational European trial will enroll 142 patients…

Janssen Pharmaceuticals Logo

New real-world data highlight health and financial impact of caring for an adult with schizophrenia

Industry news / 11 November 2014 / Janssen

Compared with their peers and other caregivers, carers for adults with schizophrenia report deteriorated physical and mental health and greater health resource usage/utilisation…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...